Table 2. Patient Characteristics According to Treatment Modality Groups.
| Variables | Groups | RT alone, n (%) | CT+RT, n (%) | CCRT, n (%) | p value |
|---|---|---|---|---|---|
| Sex | Male | 10 (53) | 12 (75) | 12 (60) | 0.395 |
| Female | 9 (47) | 4 (25) | 8 (40) | ||
| Age (yrs) | ≥60 | 12 (63) | 14 (88) | 12 (60) | 0.169 |
| <60 | 7 (37) | 2 (12) | 8 (40) | ||
| Stage | I | 15 (79) | 11 (69) | 13 (65) | 0.656 |
| II | 4 (21) | 5 (31) | 7 (35) | ||
| Performance | ECOG 0, 1 | 19 (100) | 16 (100) | 17 (85) | 0.102 |
| ECOG 2 | 0 (0) | 0 (0) | 3 (15) | ||
| Primary site | Sinonasal | 15 (79) | 13 (81) | 19 (95) | 0.352 |
| Others | 4 (21) | 3 (19) | 1 (5) | ||
| Serum LDH | Elevated | 5 (71) | 9 (82) | 12 (60) | 0.476 |
| Normal | 2 (29) | 2 (18) | 8 (40) | ||
| B symptoms | Yes | 3 (16) | 3 (19) | 7 (35) | 0.376 |
| No | 16 (84) | 13 (81) | 13 (65) | ||
| IPI | 1 | 10 (53) | 7 (44) | 4 (20) | 0.225 |
| 2 | 8 (42) | 8 (50) | 12 (60) | ||
| 3 | 1 (5) | 1 (6) | 4 (20) | ||
| NKPI | Group 1 | 10 (53) | 5 (31) | 4 (20) | 0.302 |
| Group 2 | 7 (37) | 6 (38) | 8 (40) | ||
| Group 3 | 2 (11) | 4 (25) | 7 (35) | ||
| Group 4 | 0 (0) | 1 (6) | 1 (5) |
RT, radiotherapy; CT, chemotherapy; CCRT, concurrent chemoradiotherapy; ECOG, Eastern Cooperative Oncology Group; IPI, international prognostic index; LDH, lactate dehydrogenase; NKPI, NK/T cell lymphoma prognostic index.6